Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lumos Pharma (LUMO)
NASDAQ:LUMO
Lumos Pharma (LUMO) Stock Price & Analysis
332 Followers
LUMO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.37 - $4.55
Previous Close$1.46
Volume9.46K
Average Volume (3M)34.09K
Market Cap
$11.85M
Enterprise Value-$10.83M
Total Cash (Recent Filing)$23.20M
Total Debt (Recent Filing)$518.00K
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 12, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.59
Shares Outstanding8,116,488
10 Day Avg. Volume11,725
30 Day Avg. Volume34,091
Standard Deviation0.27
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.04
Price to Sales (P/S)35.35
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-7.79
Enterprise Value/Gross Profit-5.28
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$18.00Price Target Upside1132.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Lumos Pharma News
PremiumCompany Announcements
Lumos Pharma Announces Governance Decisions and Trial Updates
PremiumPre-Earnings
Is LUMO a Buy, Before Earnings?Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LUMO FAQ
What was Lumos Pharma’s price range in the past 12 months?
Lumos Pharma lowest stock price was $1.37 and its highest was $4.55 in the past 12 months.
What is Lumos Pharma’s market cap?
Currently, no data Available
When is Lumos Pharma’s upcoming earnings report date?
Lumos Pharma’s upcoming earnings report date is Nov 12, 2024 which is in 114 days.
How were Lumos Pharma’s earnings last quarter?
Lumos Pharma released its earnings results on May 14, 2024. The company reported -$1.29 earnings per share for the quarter, missing the consensus estimate of -$1.136 by -$0.154.
Is Lumos Pharma overvalued?
According to Wall Street analysts Lumos Pharma’s price is currently Undervalued.
Does Lumos Pharma pay dividends?
Lumos Pharma does not currently pay dividends.
What is Lumos Pharma’s EPS estimate?
Lumos Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lumos Pharma have?
Lumos Pharma has 8,116,488 shares outstanding.
What happened to Lumos Pharma’s price movement after its last earnings report?
Lumos Pharma reported an EPS of -$1.29 in its last earnings report, missing expectations of -$1.136. Following the earnings report the stock price went down -12.157%.
Which hedge fund is a major shareholder of Lumos Pharma?
Among the largest hedge funds holding Lumos Pharma’s share is Blackstone Inc.. It holds Lumos Pharma’s shares valued at 222K.
---
Lumos Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (1132.88% Upside)
$18.00 (1132.88% Upside)
Hedge Fund Trend
Decreased
By 247.9K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.37%
12-Months-Change
Fundamentals
Return on Equity
-106.15%
Trailing 12-Months
Asset Growth
-55.94%
Trailing 12-Months
Company Description
Lumos Pharma
NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.
---
LUMO Earnings Call
Q1 2024
0:00 / 0:00
---
LUMO Stock 12 Month Forecast
Average Price Target
$18.00
▲(1132.88% Upside)
Technical Analysis
Best Analysts Covering LUMO
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-34.79%
reiterated a buy rating 5 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -34.79% per trade.
---